Association between HCV infection and diabetes type 2 in Egypt: Is it time to split up? by Cuadros, D.F. (Diego F.) et al.
lable at ScienceDirect
Annals of Epidemiology 25 (2015) 918e923Contents lists avaiAnnals of Epidemiology
journal homepage: www.annalsofepidemiology.orgOriginal articleAssociation between HCV infection and diabetes type 2 in Egypt: is
it time to split up?Diego F. Cuadros PhD a,b,*, F. DeWolfe Miller PhD c, Nico Nagelkerke PhD d, Laith J. Abu-Raddad PhD a,b,e
a Infectious Disease Epidemiology Group, Weill Cornell Medical CollegedQatar, Cornell University, Qatar FoundationdEducation City, Doha, Qatar
bDepartment of Healthcare Policy and Research, Weill Cornell Medical College, Cornell University, New York, NY
cDepartment of Tropical Medicine and Medical Microbiology and Pharmacology, University of Hawaii, Honolulu
dDepartment of Public Health, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
eVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WAa r t i c l e i n f o
Article history:
Received 9 June 2015
Accepted 7 September 2015
Available online 28 September 2015
Keywords:
Hepatitis C virus
Diabetes
Egypt
Chronic infectionThe authors declare that there are no conﬂicts of
* Corresponding author. Weill Cornell Medical Co
tiondEducation City, P.O. Box 24144, Doha, Qa
fax: þ974-4492-8222.
E-mail address: dfc2002@qatar-med.cornell.edu (D
http://dx.doi.org/10.1016/j.annepidem.2015.09.005
1047-2797/ 2015 The Authors. Published by Elseviera b s t r a c t
Purpose: There is a conﬂicting evidence about the association between hepatitis C virus (HCV) infection
and diabetes mellitus. The objective of this study was to assess this association in Egypt, the country with
the highest HCV prevalence in the world.
Methods: The source of data was from the Egypt Demographic and Health Survey conducted in 2008.
Using multivariable logistic regression analyses to account for known confounders, the association
was investigated at two levels’]: (1) HCV exposure (HCV antibody status) and diabetes mellitus and
(2) diabetes mellitus and chronic HCV infection (HCV RNA status) among HCV-exposed individuals.
Results: We found no evidence for an association between HCV antibody status and diabetes (adjusted
odds ratio [OR] ¼ 0.87; 95% conﬁdence interval [CI], 0.63e1.19). However, among HCV-exposed in-
dividuals, we found an evidence for an association between diabetes and active HCV infection (adjusted
OR ¼ 2.44, 95% CI, 1.30e4.57).
Conclusions: Although it does not appear that HCV exposure and diabetes are linked, there might be an
association between diabetes and chronic HCV infection. The HCVediabetes relationship may be more
complex than previously anticipated. Therefore, a call for an “amicable divorce” to the HCVediabetes
relationship could be premature.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatitis C virus (HCV) infection and diabetes mellitus are the
major public health challenges with increasing morbidity and
mortality disease burden [1, 2]. HCV is a multifaceted infection
affecting different processes such as mitochondrial function, insulin
resistance, lipid metabolism, and signaling pathways among others
[3, 4]. HCV infection can lead to inﬂammation of the liver, pro-
gression to ﬁbrosis, and development of cirrhosis or hepatocellular
carcinoma [4]. Diabetes has been also recognized as part of the
spectrum of HCV-associated diseases [5]. Diabetes mellitus is a
complex disease with pathophysiology that includes increased
hepatic glucose production, defects in insulin secretion, and/or in-
sulin resistance [6, 7].interest.
llegedQatar, Qatar Founda-
tar. Tel.: þ974-4492-8321;
.F. Cuadros).
Inc. This is an open access article uThe precise biological mechanisms underlining glucose intoler-
ance and diabetes in HCV-infected individuals are not completely
understood. Several hypotheses, however, have been proposed for
the development of diabetes mellitus in HCV-infected individuals.
Alterations in hepatic lipid and carbohydrate metabolismwith HCV
infection have been commonly observed, potentially causing fat
accumulation in hepatocytes [8, 9]. This intracellular fat accumu-
lation could induce insulin resistance and may lead to the devel-
opment of diabetes [10]. Moreover, studies have suggested that
expression of the HCV core protein can induce hepatic insulin
resistance through alterations in signaling in the insulin receptor
substrate-1 pathway [11, 12]. Results derived from animal models
have also suggested a more direct effect of HCV infection on insulin
resistance in the liver through the activity of hepatic tumor necrosis
factor-a on the insulin signaling pathway [13].
Emerging epidemiologic evidence has suggested a link between
HCV infection and diabetes [5,14e17]. However, most epidemio-
logic studies reported analyses from data derived from tertiary
liver care centers [16, 17]. Such clinic-based studies may suffer from
selection bias, and recruited liver patients may not represent thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Determination of study sample.
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tion. Only few population-based studies have been conducted to
assess this association, and their results were inconclusive [18e21].
Notably, a recent landmark study on a nationally representative
sample of the U.S. population, the National Health and Nutrition
Examination Survey (NHANES), failed to identify a statistically
signiﬁcant association between HCV infection and diabetes [22].
The study included more than 15,000 participants, of whom 277
participants were HCV antibody positive [22]. The lack of a clear
association between HCV infection and diabetes in this study, along
with the accumulating conﬂicting evidence from other studies [16,
17,19, 20, 23], casts doubt on the existence of a causal link leading to
a call for an “amicable divorce” to this association [7].
A major concern about the U.S.-based study and the other
population-based studies has been the relatively small number of
HCV infected individuals included in the analyses, because of the
low HCV prevalence in the population [16, 20]. For example, HCV
prevalence in the U.S. population is only 1.7% [22]. Therefore, there
may not have been sufﬁcient statistical power in these studies to
characterize the complexity of the association between HCV and
diabetes. It is critical, as has been suggested recently [22], to
replicate such studies on nationally representative samples in
countries with high HCV prevalence where such samples may
include a large number of HCV infected individuals.
In the present study, we aimed to examine the association be-
tweenHCV infection and diabetes in a large nationally representative
population-based sample in Egypt, the country with the highest HCV
prevalence worldwide (14.7%) [24e26], with genotype 4 being the
dominant genotype (responsible for more than 90% of HCV in-
fections) countrywide [26]. This sample offers a rare opportunity to
examine this association as it is one of the largest samples ever to
study HCV infection [24] and conducted in a country where HCV
prevalence ismore than 10-fold higher than that in the United States.
[24, 25]. The sample includedmore than 1400HCV antibody-positive
individuals [24], compared to only 277 in the U.S. study [22]. The
ﬁrst objective of our study was to assess the association between
diabetes mellitus and HCV exposure (antibody positivity) in Egypt.
The second objective was to assess the association between chronic
HCV infection (HCV RNA positivity) and diabetes mellitus in the
subsample of HCV antibody-positive individuals.
Materials and methods
Conceptual framework
The association between HCV infection and diabetes can be
manifested at different levels. At one level, HCV-exposed in-
dividuals (i.e., HCV antibody positive) could be at higher risk of
developing diabetes. Conversely, diabetic patients could also be
more frequently exposed to HCV through medical procedures, and
thus have a higher likelihood of becoming infected. Therefore, we
assessed the association between diabetes mellitus and HCV anti-
body serological status in the whole sample (Model 1).
On another level, diabetic patients could be less likely to clear
the infection if they are exposed to the virus. Alternatively, in-
dividuals with chronic HCV infection (i.e., HCV RNA positive) could
bemore likely to develop diabetes. Therefore, we also examined the
relationship at this level by assessing the association between HCV
RNA status and diabetes mellitus among only the subsample of HCV
antibody-positive individuals (Model 2).
Data sources
Our source of data was the Egypt Demographic and Health
Survey (EDHS) conducted in 2008 [24]. All women andmen aged 15to 59 years present in the sampled households were eligible for the
survey, and 11,126 (87.1%) of these individuals were tested for
HCV antibody and HCV RNA. The HCV testing protocol included
an initial round of testing to detect the presence of antibodies
against the virus [24]. A third generation Enzyme Immunoassay
(ELISA), Adlatis EIAgen HCV Ab test (Adaltis Inc., Montreal, Canada)
was used to test for antibodies against HCV. This test showed
100% of sensitivity and 98.1% of speciﬁcity, with a cut-off value
(signal-to-cut-off ratio, S/CO) of 1.0 or more to be considered
reactive for anti-HCV antibodies, whereas those S/CO less than
1.0 were considered nonreactive [27]. All positives with this test
were conﬁrmed by a Chemiluminescent Microplate Immunoassay
(CIA) [24]. All conﬁrmed HCV antibody-positive specimens were
tested by Quantitative real time PCR (RT-qPCR) for the detection
of HCV RNA [24]. Further methodologic details related to specimen
handling and laboratory methods used for the detection of HCV
antibody and HCV RNA can be found in El-Zanaty et al. [24].
We used the binary answer to the question “has a doctor or other
health professional ever told you that you had diabetes?” as the
measure for diabetes mellitus. After excluding participants with
missing HCV antibody status or diabetes status, the ﬁnal analyses
were conducted on 10,143 participants (Fig. 1).Statistical analyses
We conducted two separate analyses. In the ﬁrst model, the
dichotomous HCV antibody serological status (indicator of expo-
sure to HCV) was included as independent variable, and diabetes
status was the main outcome (model 1). In the second model,
diabetes status was included as independent variable, and HCV RNA
status (indicator of active infection) among HCV antibody-positive
individuals was the main outcome (model 2). To adjust for con-
founders, several variables known to be associated with HCV
infection or diabetes were ﬁrst analyzed in bivariate analyses.
Variables includedwere age, place of residence (urban or rural), sex,
level of education, body mass index (BMI), hypertension, ever had
dental treatment, ever had surgery, ever had blood transfusion, ever
had received parenteral antischistosomiasis therapy (PAT), and ever
been hospitalized. BMI was stratiﬁed in three categories: normal
(BMI < 25), overweight (BMI ¼ 25e30), and obese (BMI > 30) [28].
D.F. Cuadros et al. / Annals of Epidemiology 25 (2015) 918e923920Hypertension was deﬁned according to the guidelines of the Joint
National Committee on Detection, Evaluation, and Treatment of
High Blood Pressure [29].
Multivariable logistic regressions were performed to determine
the association between diabetes and HCV serological status or HCV
RNA status. Variables with a P value less than .25 in bivariate ana-
lyses were included in the ﬁnal multivariable logistic models. Age
was included as a polynomial term to account for nonlinearities in
the association with diabetes. Analyses included sample weights to
account for unequal selection probabilities and nonresponses. All
statistical analyses were conducted using SAS, version 9.3 [30].Sensitivity analyses
We evaluated the robustness of the results obtained from the
multivariable regression models using three different approaches.
First, the cut-off of the P value in the bivariate analyses was varied
to be smaller (P < .2) or larger (P < .5) than the default cut-off
implemented in the selection criteria for the ﬁnal multivariable
model (P < .25). Second, alternative multivariable models wereTable 1
Demographics and study population characteristics
Variable Diabetes, n (%) HCV antib
Negative (n ¼ 9792) Positive (n ¼ 351) Negative
Diabetes
Negative d d 8442 (85.
Positive d d 259 (73.
Age (y)
15e19 1786 (99.77) 6 (0.23) 1723 (96.
20e24 1664 (99.79) 6 (0.21) 1595 (95.
25e29 1390 (99.88) 4 (0.12) 1305 (93.
30e34 1131 (99.04) 12 (0.96) 1022 (88.
35e39 1018 (98.15) 23 (1.85) 912 (86.
40e44 939 (95.88) 45 (4.12) 760 (76.
45e49 785 (91.42) 74 (8.58) 601 (69.
50e54 591 (87.72) 82 (12.28) 420 (60.
55e59 488 (83.47) 99 (16.53) 363 (59.
Area
Urban 3885 (40.69) 198 (58.47) 3674 (89.
Rural 5907 (59.31) 153 (41.53) 5027 (81.
Sex
Male 4624 (97.37) 136 (2.63) 3932 (81.
Female 5168 (95.99) 215 (4.01) 4769 (87.
Education
None 2170 (94.87) 123 (5.14) 1778 (75.
Primary 1349 (94.17) 84 (5.83) 1148 (79.
Secondary 4844 (97.96) 107 (2.04) 4448 (89.
Higher education 1429 (97.47) 37 (2.53) 1327 (90.
BMI
Normal (less than 25) 748 (97.93) 16 (2.07) 660 (86.
Overweight (25e30) 870 (98.20) 17 (1.80) 764 (86.
Obese (more than 30) 1186 (95.38) 63 (4.62) 1075 (85.
Hypertension
Normal 8436 (97.00) 269 (3.00) 7564 (86.
Prehypertensive 1356 (94.62) 82 (5.38) 1137 (78.
Ever had dental treatment
Yes 5816 (95.86) 263 (4.14) 5089 (82.
No 3970 (97.94) 88 (2.06) 3608 (88.
Ever had a surgical procedure
Yes 3989 (95.24) 202 (4.76) 3491 (82.
No 5793 (97.74) 148 (2.26) 5201 (86.
Ever had a blood transfusion
Yes 381 (91.16) 31 (8.84) 320 (75.
No 9392 (96.88) 320 (3.12) 8365 (85.
Ever received PAT
Yes 859 (95.50) 46 (4.50) 633 (69.
No 8789 (96.77) 298 (3.23) 7947 (86.
Ever been hospitalized
Yes 299 (97.1) 9 (2.9) 260 (84.
No 9493 (96.4) 342 (3.5) 8441 (85.performed excluding variables that were not statistically signiﬁcant
in the ﬁnal multivariable models, but retaining the variables that
were statistically signiﬁcant at P < .05. Finally, a study conducted
using diabetes self-reported data fromNHANES (1988e1994) found
no statistically signiﬁcant association between HCV and diabetes
overall, but a signiﬁcant association among individuals older than
40 years of age [19]. Therefore, we conducted also a subgroup
analysis restricted to individuals older than 40 years.Results
General results
The general characteristics of the study subjects are listed in
Table 1. From the sampled population, 351 individuals reported to
have diabetes corresponding to a diabetes prevalence of 3.33% (95%
conﬁdence interval [CI], 2.94e3.71). Females had higher prevalence
of diabetes, 4.01% (95% CI, 3.42e4.60), than males, 2.63% (95% CI,
2.13e3.13). Diabetes was more prevalent in urban areas, 4.72% (95%
CI, 3.98e5.46), than in rural areas, 2.35% (95% CI, 1.96e2.76). Theody, n (%) HCV RNA, n (%)
(n ¼ 8701) Positive (n ¼ 1442) Negative (n ¼ 464) Positive (n ¼ 978)
44) 1320 (14.56) 8888 (90.35) 904 (9.65)
10) 92 (26.90) 277 (77.71) 74 (22.29)
07) 69 (3.93) 1741 (97.22) 51 (2.78)
39) 75 (4.61) 1629 (97.33) 41 (2.67)
64) 89 (6.36) 1333 (95.91) 61 (4.09)
15) 121 (11.85) 1060 (91.68) 83 (8.32)
26) 129 (13.74) 945 (90.03) 96 (9.97)
16) 224 (23.84) 836 (84.36) 148 (15.64)
89) 258 (30.11) 688 (80.19) 171 (19.81)
97) 253 (39.03) 498 (73.64) 174 (23.36)
05) 224 (40.95) 435 (72.04) 152 (27.96)
58) 409 (10.42) 3787 (92.61) 296 (88.04)
82) 1033 (18.18) 5378 (88.04) 682 (11.96)
99) 828 (18.01) 4183 (87.52) 577 (12.48)
97) 614 (12.03) 4982 (92.26) 401 (7.74)
56) 515 (24.44) 1941 (83.31) 352 (16.69)
03) 285 (20.97) 1257 (86.90) 176 (13.10)
20) 503 (10.80) 4590 (92.46) 361 (7.54)
79) 139 (9.21) 1377 (94.09) 89 (5.91)
03) 104 (13.97) 699 (91.24) 65 (8.76)
39) 123 (13.61) 801 (91.13) 86 (8.87)
24) 174 (14.76) 1140 (90.90) 109 (9.10)
06) 1141 (13.94) 7930 (90.61) 775 (9.39)
74) 301 (21.26) 1235 (85.79) 203 (14.21)
91) 990 (17.09) 5398 (88.34) 681 (11.66)
37) 450 (11.63) 6079 (92.45) 3763 (7.55)
62) 700 (17.38) 3704 (87.88) 487 (12.12)
81) 740 (13.19) 5452 (91.46) 489 (8.54)
10) 92 (24.90) 350 (83.12) 62 (16.88)
42) 1347 (14.58) 8799 (86.48) 913 (9.39)
07) 272 (30.93) 722 (79.38) 183 (20.62)
59) 1140 (13.41) 8309 (90.93) 778 (9.07)
4) 48 (15.6) 274 (88.9) 34 (11.1)
2) 1394 (14.2) 8891 (90.4) 944 (9.6)
Table 2
Unadjusted and adjusted results for diabetes mellitus status as the outcome
according to selected covariates (model 1)
Variable Unadjusted Adjusted*
OR 95% CI P OR 95% CI P
HCV antibody
Negative ref ref
Positive 2.16 1.65e2.82 <.01 0.87 0.63e1.19 .38
Area
Urban ref ref
Rural 0.49 0.38e0.62 <.01 0.60 0.45e0.80 <.01
Sex
Male ref ref
Female 1.59 1.21e1.98 <.01 1.88 1.39e2.55 <.01
Education
None ref ref
Primary 1.14 0.83e1.57 <.01 1.30 0.91e1.84 .67
Secondary 0.38 0.28e0.52 <.01 1.23 0.86e1.77 .51
Higher education 0.48 0.31e0.75 .02 1.07 0.66e1.73 .28
BMI
Normal (less than 25) ref ref
Overweight (25e30) 0.87 0.40e1.90 .06 1.37 0.73e2.54 .44
Obese (more than 30) 2.29 1.26e4.17 <.01 0.61 0.28e1.33 .37
Hypertension
Normal ref ref
Prehypertensive 1.84 1.39e2.44 <.01 1.17 0.86e1.60 .32
Ever had dental treatment
No ref ref
Yes 2.05 1.60e2.61 <.01 1.16 0.86e1.56 .33
Ever had a surgical procedure
No ref ref
Yes 2.26 1.70e2.74 <.01 1.27 0.92e1.78 .06
Ever had a blood transfusion
No ref ref
Yes 3.01 1.93e4.71 <.01 1.78 0.97e2.97 .06
Ever received PAT
No ref ref
Yes 1.14 0.99e2.01 .14 1.06 0.71e1.60 .13
Ever been hospitalized
No ref
Yes 0.77 0.35e1.68 .50 d d d
* The model also includes adjustment for age.
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(95% CI, 47e49), compared with 32 years (95% CI, 31e33) of those
who did not.
From the sampled population, 1442 individuals were HCV
antibody positive corresponding to an HCV antibody prevalence
of 14.22% (95% CI, 13.54e14.91) were HCV antibody positive,
whereas 9.64% (95% CI, 9.07e10.23) was HCV RNA positive. HCV
antibody prevalence was higher in rural areas, 17.04% (95% CI,
16.10e18.01), than in urban settings, 10.02% (95% CI, 9.07e10.23).
The mean age of HCV antibody-positive individuals was 43 years
(95% CI, 42e44), compared to 31 years (95% CI, 30e32) of those
HCV antibody negative.
Association between HCV exposure and diabetes (model 1)
The prevalence of diabetes in HCV antibody-positive individuals
was 5.98% (95% CI, 4.67e7.30), whereas the prevalence of diabetes
in HCV antibody negative individuals was 2.86% (95% CI, 2.47e3.25).
There was an association between diabetes and HCV exposure in
bivariate analysis with an unadjusted crude odds ratio (OR) of 2.16
(95% CI, 1.65e2.82). From the covariates included in the study, only
ever been hospitalized (P ¼ 0.5) was not included in the ﬁnal
multivariable model (model 1). After adjusting for the other vari-
ables, HCV exposure status was no longer associated with diabetes
status (Table 2). The adjusted OR was 0.87 (95% CI, 0.63e1.19).
Association between chronic HCV infection and diabetes among HCV
exposed (model 2)
Among HCV antibody-positive individuals, 82.84% (95% CI,
74.25e91.44) of the individuals who reported diabetes were HCV
RNA positive. In contrast, only 66.26% (95% CI, 63.55e68.98) of the
individuals who did not report diabetes had an active HCV infec-
tion. There was an association between HCV RNA status and dia-
betes in bivariate analysis with unadjusted crude OR of 2.46 (95% CI,
1.34e4.53). From the covariates included in the study age
(P¼ 0.79), BMI (P¼ 0.89), hypertension (P¼ 0.86), ever had a blood
transfusion (P ¼ 0.91), ever received PAT (P ¼ 0.76), and ever been
hospitalized (P ¼ 0.39) were not included in the ﬁnal multivariable
model (model 2). After adjusting for the other remaining variables,
individuals who were HCV antibody positive and reported diabetes
had more than two times higher odds of having an active infection
than HCV antibody-positive individuals who did not report diabetes
(Table 3). The adjusted OR was 2.44 (95% CI, 1.30e4.57). It is worth
noting that sex was also associated with HCV RNA status. Our
analysis suggests that in females the likelihood of having an active
infection is lower compared to males, with an adjusted OR of 0.72
(95% CI, 0.56e0.91).
Sensitivity analyses
Sensitivity analyses indicated that modifying the cut-off of the
P value for inclusion in the ﬁnal multivariable models did not affect
our results. Likewise, by removing the variables that lacked statis-
tical signiﬁcance in the ﬁnal multivariable models, or by including
only individuals older than 40 years, the associations estimated in
both models for HCV exposure (model 1) or diabetes (model 2)
were almost the same as the estimations using the full ﬁnal models
(data not shown).
Discussion
HCV exposure was not associated with diabetes in this nation-
ally representative population-based survey in Egypt, the country
with the highest HCV prevalence in the world. After adjusting forconfounders, our results indicated that HCV antibody-positive in-
dividuals did not have higher odds of having diabetes, thereby
corroborating results of the recent U.S.-based survey [22]. As the
Egypt sample was composed of more than 10,000 subjects, with
more than 1400 HCV antibody-positive individuals, it is not likely
that the lack of association could be explained by insufﬁcient sta-
tistical power. Although we found no association between HCV
exposure and diabetes, we identiﬁed an association between dia-
betes and chronic HCV infection in those who have been exposed to
HCV. Diabetics were found to be less likely to have a cleared HCV
infection than those who were not diabetic. To our knowledge, this
is the ﬁrst evidence that suggests the possibility of a biological
interaction between the two conditions, but only among those HCV
antibody-positive individuals. This ﬁnding highlights how the
conﬂicting evidence about the association between HCV infection
and diabetes could have been obscured by the complexity of this
association and underlying causal links. Although HCV exposure
and diabetes do not appear to be associated, diabetes and HCV
chronic infection appear to be associated with a sizeable effect size.
Additional research is justiﬁed to investigate this association and
to identify possible causal links between these two conditions.
We conducted several sensitivity analyses to examine the
robustness of our ﬁndings. These analyses indicated that the
results are consistent regardless of changes in the P value for
the variable inclusion criteria or exclusion of individuals younger
than 40 years. The latter contrasts with a similar study, using
the NHANES 1988e1994 self-reported data, which found no
Table 3
Unadjusted and adjusted results for HCV RNA status among HCV antibody-positive
individuals as the outcome according to selected covariates (model 2)
Variable Unadjusted Adjusted*
OR 95% CI P OR 95% CI P
Diabetes
Negative ref ref
Positive 2.46 1.34e4.53 <.01 2.44 1.30e4.57 <.01
Area
Urban ref ref
Rural 0.79 0.60e1.05 .10 0.83 0.62e1.11 .19
Sex
Male ref ref
Female 0.80 0.64e0.99 .05 0.72 0.56e0.91 <.01
Education
None ref ref
Primary 0.77 0.56e1.08 .16 0.68 0.48e1.06 .10
Secondary 1.07 0.81e1.16 .10 0.97 0.72e1.31 .19
Higher education 0.83 0.55e1.26 .55 0.70 0.46e1.08 .14
BMI
Normal (less than 25) ref ref
Overweight (25e30) 1.12 0.61e2.03 .38 d d d
Obese (more than 30) 0.96 0.56e1.63 .89 d d d
Hypertension
Normal ref d d d
Prehypertensive 0.98 0.73e1.29 .86 d d d
Ever had dental treatment
No ref ref
Yes 1.16 0.91e1.49 .24 1.08 0.84e1.37 .50
Ever had a surgical procedure
No ref ref
Yes 1.25 1.00e1.57 .05 1.26 0.98e1.59 .06
Ever had a blood transfusion
No ref d d d
Yes 1.03 0.62e1.70 .91 d d d
Ever received PAT
No ref d d d
Yes 0.96 0.71e1.29 .76 d d
Ever been hospitalized
No ref d d d
Yes 1.33 0.69e2.57 .39 d d d
* The model also includes adjustment for age.
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ation among individuals older than 40 years [19].
With the cross-sectional design of our study, the direction of the
relationship between diabetes and chronic HCV infection is un-
certain. The higher likelihood of diabetics having an active infection
could possibly be a manifestation of a biological effect of chronic
HCV infection on the development of diabetes, as it has been pre-
viously reported [31], or a biological effect of diabetes on the nat-
ural history of HCV infection. For example, diabetics may have an
impaired ability to clear HCV infection. It is also possible that a
nonbiological relationship may explain the association such as di-
abetics being more exposed to HCV infection through frequent
medical procedures. The latter, however, would seem unlikely as
we found no evidence for an association between HCV exposure
and diabetes (Table 2), and we controlled in our analyses for
exposure to different medical procedures (Table 3).
We used self-reported data for diabetes, and such data may not
have sufﬁcient sensitivity and speciﬁcity. Laboratory diagnosis is
the preferred method to investigate the associations examined in
this study [22]. Self-reported diabetes will likely underestimate
diabetes prevalence as a large fraction of diabetics are unaware of
their disease status [32]. Diabetes prevalence in this sample was
only 3.3%, much lower than that estimated for Egypt at 10.4% [33].
In addition to underdiagnosis, the EDHS sample included only
those aged 15e59 years and excluded older populations who have
a higher diabetes prevalence. This explains also part of this
difference. Despite this limitation, self-reported diabetes has beenproposed as a reasonably good approximation to diabetes status,
particularly in population-based studies [34].
An additional shortcoming in our study was the lack of labora-
tory data to adjust for other factors such as plasma alanine ami-
notransaminase (ALT) levels. Elevation of liver enzymes such as ALT
has been found to increase the risk of diabetes regardless of the
underlying liver disease. A study conducted in a Japanese popula-
tion found that HCV was no longer associated with diabetes after
adjusting for ALT [35]. But another study conducted in an Italian
cohort found that HCV was associated with diabetes only in sub-
jects with elevated ALT [18]. It has been proposed that failure to
adjust for these factors may explain the positive association be-
tween HCV and diabetes identiﬁed in several studies [22,36].
Other important study limitations may have affected our results.
Given the multiple logistical difﬁculties in conducting DHS studies,
some of our measures could be affected by inherent biases in the
data, such as response rate or refusal to HCV testing with prior
knowledge of being HCV infected [37e39]. Additionally, as we
mentioned above, genotype 4 is responsible for more than 90%
of the HCV infections in Egypt [26], and whether the association
of diabetes and HCV infection in genotype 4 discussed here can be
generalized to other genotypes is uncertain.
Conclusions
In sum, using data from one of the largest nationally represen-
tative surveys of HCV infection ever conducted, we found no evi-
dence for an association between HCV exposure and diabetes. More
importantly, however, we found evidence for an association be-
tween diabetes and chronic HCV infection in HCV-exposed in-
dividuals. The existence of such association suggests that the
HCVediabetes relationship could be more complex than previously
anticipated. A call for an “amicable divorce” to the HCVediabetes
relationship [36] could be premature.
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